Publicité
La bourse ferme dans 2 h 15 min
  • CAC 40

    8 216,69
    +11,88 (+0,14 %)
     
  • Euro Stoxx 50

    5 089,80
    +8,06 (+0,16 %)
     
  • Dow Jones

    39 760,62
    +0,54 (+0,00 %)
     
  • EUR/USD

    1,0810
    -0,0020 (-0,18 %)
     
  • Gold future

    2 226,90
    +14,20 (+0,64 %)
     
  • Bitcoin EUR

    65 432,25
    +1 596,63 (+2,50 %)
     
  • CMC Crypto 200

    885,54
    0,00 (0,00 %)
     
  • Pétrole WTI

    82,44
    +1,09 (+1,34 %)
     
  • DAX

    18 496,12
    +19,03 (+0,10 %)
     
  • FTSE 100

    7 959,59
    +27,61 (+0,35 %)
     
  • Nasdaq

    16 383,45
    -16,08 (-0,10 %)
     
  • S&P 500

    5 249,90
    +1,41 (+0,03 %)
     
  • Nikkei 225

    40 168,07
    -594,66 (-1,46 %)
     
  • HANG SENG

    16 541,42
    +148,58 (+0,91 %)
     
  • GBP/USD

    1,2640
    +0,0002 (+0,02 %)
     

EDAP TMS SA to Announce Third Quarter 2020 Financial Results on November 18, 2020

Company to host conference call and webcast on Thursday, November 19 at 8:30 am EDT

LYON, France, November 9, 2020 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the third quarter ended September 30, 2020 after the markets close on Wednesday, November 18, 2020.

An accompanying conference call and webcast will be conducted by Marc Oczachowski, Chairman of the Board and Chief Executive Officer, and François Dietsch, Chief Financial Officer. The call will be held at 8:30am EDT on Thursday, November 19, 2020. Please refer to the information below for conference call dial-in information and webcast registration.

Conference Call & Webcast
Thursday, November 19th @ 8:30am Eastern Time
Domestic: 877-451-6152
International: 201-389-0879
Passcode: 13712293
Webcast: http://public.viavid.com/index.php?id=142115

PUBLICITÉ

About EDAP TMS SA

A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, and us.hifu-prostate.com.

CONTACTS:
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com

Investor Contact
Jeremy Feffer
LifeSci Advisors, LLC
212-915-2568
jeremy@lifesciadvisors.com